[go: up one dir, main page]

GB202311984D0 - Optimised fc molecules - Google Patents

Optimised fc molecules

Info

Publication number
GB202311984D0
GB202311984D0 GBGB2311984.5A GB202311984A GB202311984D0 GB 202311984 D0 GB202311984 D0 GB 202311984D0 GB 202311984 A GB202311984 A GB 202311984A GB 202311984 D0 GB202311984 D0 GB 202311984D0
Authority
GB
United Kingdom
Prior art keywords
optimised
molecules
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Ceased
Application number
GBGB2311984.5A
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Petmedix Ltd
Original Assignee
Petmedix Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Petmedix Ltd filed Critical Petmedix Ltd
Priority to GBGB2311984.5A priority Critical patent/GB202311984D0/en
Publication of GB202311984D0 publication Critical patent/GB202311984D0/en
Priority to PCT/GB2024/052055 priority patent/WO2025032320A1/en
Ceased legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2887—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against CD20
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/31—Immunoglobulins specific features characterized by aspects of specificity or valency multispecific
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/52—Constant or Fc region; Isotype
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/52—Constant or Fc region; Isotype
    • C07K2317/524—CH2 domain
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/52—Constant or Fc region; Isotype
    • C07K2317/526—CH3 domain
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/52—Constant or Fc region; Isotype
    • C07K2317/53—Hinge
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/94—Stability, e.g. half-life, pH, temperature or enzyme-resistance

Landscapes

  • Chemical & Material Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Immunology (AREA)
  • General Health & Medical Sciences (AREA)
  • Biophysics (AREA)
  • Biochemistry (AREA)
  • Genetics & Genomics (AREA)
  • Medicinal Chemistry (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Peptides Or Proteins (AREA)
GBGB2311984.5A 2023-08-04 2023-08-04 Optimised fc molecules Ceased GB202311984D0 (en)

Priority Applications (2)

Application Number Priority Date Filing Date Title
GBGB2311984.5A GB202311984D0 (en) 2023-08-04 2023-08-04 Optimised fc molecules
PCT/GB2024/052055 WO2025032320A1 (en) 2023-08-04 2024-08-02 Optimised fc molecules

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
GBGB2311984.5A GB202311984D0 (en) 2023-08-04 2023-08-04 Optimised fc molecules

Publications (1)

Publication Number Publication Date
GB202311984D0 true GB202311984D0 (en) 2023-09-20

Family

ID=88017062

Family Applications (1)

Application Number Title Priority Date Filing Date
GBGB2311984.5A Ceased GB202311984D0 (en) 2023-08-04 2023-08-04 Optimised fc molecules

Country Status (2)

Country Link
GB (1) GB202311984D0 (en)
WO (1) WO2025032320A1 (en)

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU2018281045A1 (en) * 2017-06-05 2019-12-12 Janssen Biotech, Inc. Engineered multispecific antibodies and other multimeric proteins with asymmetrical CH2-CH3 region mutations
CN111182915A (en) * 2017-08-15 2020-05-19 金德雷德生物科学股份有限公司 Veterinary IgG Fc variants
CN112867732A (en) * 2018-11-21 2021-05-28 瑞泽恩制药公司 Anti-staphylococcal antibodies and uses thereof
CN120904316A (en) * 2018-12-27 2025-11-07 伊兰科美国公司 Veterinary IgG Fc variants
GB202005879D0 (en) 2020-04-22 2020-06-03 Petmedix Ltd Heterodimeric proteins
WO2021231464A1 (en) * 2020-05-11 2021-11-18 Invetx Inc. Compositions for increasing half-life of a therapeutic agent in canines and methods of use
AU2022321899A1 (en) 2021-08-06 2024-02-08 Zoetis Services Uk Limited Antibody fc variants

Also Published As

Publication number Publication date
WO2025032320A1 (en) 2025-02-13

Similar Documents

Publication Publication Date Title
EP3906057A4 (en) Anti-tcr antibody molecules and uses thereof
IL311976A (en) Rna molecules
EP4007967A4 (en) Multiply-accumulate unit
EP3966729A4 (en) Document auto-completion
IL289266A (en) Novel molecules
EP4247424A4 (en) Bi-functional molecules
EP3911680A4 (en) Lilrb3-binding molecules and uses therefor
EP3794027A4 (en) Optimized gp41-binding molecules and uses thereof
GB202311984D0 (en) Optimised fc molecules
EP3986882A4 (en) Beta-lactam-cannabinoid conjugate molecules
GB202318520D0 (en) Molecules
GB202308142D0 (en) Molecules
HK40087043A (en) Protease-processed molecules
HK40109231A (en) Rna molecules
HK40111881A (en) Novel multi-specific molecules
GB202020474D0 (en) Novel molecules
GB202016183D0 (en) Novel molecules
AU2019902231A0 (en) Novel molecules
HK40079005A (en) Anti-siglec-9 antibody molecules
AU2023904203A0 (en) Asymmetric RNA Molecules
AU2019901803A0 (en) Antigen-binding molecules and uses therefor
AU2019900941A0 (en) RNA molecules
HK40076629A (en) Multi-functional chimeric molecules
HK40064855A (en) Lilrb3-binding molecules and uses therefor
HK40093415A (en) Antigen-binding molecules with improved cytosol-penetrating activity

Legal Events

Date Code Title Description
AT Applications terminated before publication under section 16(1)